CEP170B

Across TCGA pan-cancer cohorts, CEP170B RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated CEP170B data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CEP170B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEP170B expression acts as an unfavorable survival marker, although some lineages such as SCLC and ESCA show a favorable association.

ACC, PRAD, and SCLC are the cancer types where CEP170B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.218	0.670	<.001	50	view →
PRAD	DFS	Tertile	All	0.822	0.918	.006	28	view →
SCLC	OS	Tertile	All	0.623	0.279	.003	26	view →
LIHC	DFS	Quartile	All	0.418	0.587	.003	25	view →
KIRP	DFS	Quartile	IV	0.098	0.786	.010	18	view →
ESCA	OS	Median	All	0.787	0.604	.002	10	view →
THYM	DFS	Tertile	III,IV	1.000	0.474	.026	9	view →
LUSC	DFS	Median	IV	0.134	0.827	.014	8	view →
THCA	DFS	Tertile	IV	0.717	0.984	.016	8	view →
COAD	OS	Tertile	All	0.721	0.860	.022	7	view →
SKCM	OS	Quartile	All	0.826	0.940	.024	6	view →
MESO	OS	Quartile	III,IV	0.310	0.599	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

CEP170B–ACC (DFS)

Open the ACC breakdown →